SWKH
SWK Holdings CorporationNASDAQFinancial ServicesAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.82
P/S
4.72
EV/EBITDA
7.28
DCF Value
$21.81
FCF Yield
18.5%
Div Yield
25.2%
Margins & Returns
Gross Margin
95.3%
Operating Margin
58.9%
Net Margin
-6.2%
ROE
-1.0%
ROA
-0.9%
ROIC
-1.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $8.0M | $-19.4M | $-1.60 |
| FY 2025 | $40.8M | $-2.5M | $-0.21 |
| Q3 2025 | $10.9M | $8.8M | $0.72 |
| Q2 2025 | $10.1M | $3.5M | $0.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Financial Services
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.30
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.